Immunotherapy for high grade glioma: current clinical practice for patients with (relapsed) GBM

Immunotherapy is emerging as a novel treatment approach in children and adults with HGG. Based on preclinical data, we are running a cohort comparison trial HGG-IMMUNO-2003 for patients with relapsed HGG. Induction vaccines consist of mature DC loaded with tumor lysate. Boost vaccines consist of only lysate. 25 patients younger than 20 years with relapsed GBM had a median PFS of 2.75m and median OS of 12.72m. Most importantly, the survival curve flattened at 19.3% after 41.8m, with patients in follow up for more than 10y. In adults, the median PFS and OS were 3.18m and 10.9m. We clearly observed a shift towards…